Trial reportJournal of clinical psychopharmacology
Factors Predicting the Efficacy of Valbenazine and Exacerbation of Tardive Dyskinesia After Valbenazine Discontinuation in Japanese Patients: A Post Hoc Analysis of the J-KINECT Study.
Trial report in Journal of clinical psychopharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo identify factors affecting valbenazine efficacy and change in tardive dyskinesia (TD) symptoms after valbenazine discontinuation using post hoc analysis of the J-KINECT study evaluating valbenazine efficacy and safety in patients with TD.
methodsJ-KINECT comprised a 6-week, placebo-controlled, double-blind period; a 42-week valbenazine extension period; and a 4-week follow-up period. Predictors for valbenazine efficacy were analyzed using multiple regression analysis for change in Abnormal Involuntary Movement Scale (AIMS) total score and logistic regression analysis for ≥50% improvement in AIMS total score, from baseline to week 6. For factors predicting changes in TD symptoms after valbenazine discontinuation, multiple regression analysis examined the change in AIMS total score from weeks 48 to 52.
resultsFactors associated with valbenazine efficacy (decrease in AIMS total score at week 6) were baseline AIMS total score and interaction terms of valbenazine dose and baseline AIMS total score (adjusted R2 =0.318). Valbenazine dose was significantly associated with ≥50% improvement in AIMS total score from baseline to week 6 [odds ratio (95% confidence interval)=1.02 (1.01, 1.03), P <0.001]. Factors associated with exacerbation of TD symptoms (increase in AIMS total score) 4 weeks after valbenazine discontinuation were baseline anticholinergic use and atypical antipsychotic use (adjusted R2 =0.182).
conclusionsAlthough multiple regression analysis did not identify strong predictors of valbenazine efficacy and change in TD symptoms after valbenazine discontinuation, valbenazine dose was associated with meaningful improvement in TD. Rather than indicating efficacy in patients with specific factors, the data suggest a possible dose-dependent trend in improvement with valbenazine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.